Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment

Patel, 2014, Clinical cancer advances 2013: annual report on progress against cancer from the American Society of Clinical Oncology, J Clin Oncol, 32, 129, 10.1200/JCO.2013.53.7076 Kris, 2014, Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs, JAMA, 311, 1998, 10.1001/jama.2014.3741 Dogan, 2012, Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers, Clin Cancer Res, 18, 6169, 10.1158/1078-0432.CCR-11-3265 Riely, 2011, A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations, J Thorac Oncol, 6, 1435, 10.1097/JTO.0b013e318223c099 Yamaguchi, 2013, Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice, Lung Cancer, 82, 31, 10.1016/j.lungcan.2013.07.013 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 Spira, 2015, Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR), J Clin Oncol, 33 Ikeda, 2016, PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer, J Thorac Oncol, 11, 62, 10.1016/j.jtho.2015.09.010 Zhu, 2014, MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer, Hum Immunol, 75, 348, 10.1016/j.humimm.2014.01.006 Fujita, 2015, The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer, Mol Ther, 23, 717, 10.1038/mt.2015.10 Chen, 2014, Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression, Nat Commun, 5, 5241, 10.1038/ncomms6241 Barsoum, 2014, A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells, Cancer Res, 74, 665, 10.1158/0008-5472.CAN-13-0992 Ribas, 2015, Adaptive immune resistance: how cancer protects from immune attack, Cancer Discov, 5, 915, 10.1158/2159-8290.CD-15-0563 Berry, 2015, Innate vs. adaptive: PD-L1-mediated immune resistance by melanoma, Oncoimmunology, 4, e1029704, 10.1080/2162402X.2015.1029704 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Zhang, 2014, Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma, Onco Targets Ther, 7, 567, 10.2147/OTT.S59959 Velcheti, 2014, Programmed death ligand-1 expression in non-small cell lung cancer, Lab Invest, 94, 107, 10.1038/labinvest.2013.130 D’Incecco, 2015, PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br J Cancer, 112, 95, 10.1038/bjc.2014.555 Azuma, 2014, Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer, Ann Oncol, 25, 1935, 10.1093/annonc/mdu242 Cooper, 2015, PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma, Lung Cancer, 89, 181, 10.1016/j.lungcan.2015.05.007 Schmidt, 2015, PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups, PLoS One, 10, e0136023, 10.1371/journal.pone.0136023 Shimoji, 2016, Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1), Lung Cancer, 98, 69, 10.1016/j.lungcan.2016.04.021 Koh, 2015, Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status, Mod Pathol, 28, 1154, 10.1038/modpathol.2015.63 Akbay, 2013, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, Cancer Discov, 3, 1355, 10.1158/2159-8290.CD-13-0310 Ota, 2015, Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer, Clin Cancer Res, 21, 4014, 10.1158/1078-0432.CCR-15-0016 Tang, 2015, The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs, Oncotarget, 6, 14209, 10.18632/oncotarget.3694 Mino-Kenudson, 2016, Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?, Cancer Biol Med, 13, 157, 10.20892/j.issn.2095-3941.2016.0009 Spigel, 2015, Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC), J Clin Oncol, 33 Dias-Santagata, 2010, Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine, EMBO Mol Med, 2, 146, 10.1002/emmm.201000070 Travis, 2011, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol, 6, 244, 10.1097/JTO.0b013e318206a221 Detterbeck, 2009, The new lung cancer staging system, Chest, 136, 260, 10.1378/chest.08-0978 Barletta, 2010, Prognostic significance of grading in lung adenocarcinoma, Cancer, 116, 659, 10.1002/cncr.24831 Dahlin, 2011, Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor, Mod Pathol, 24, 671, 10.1038/modpathol.2010.234 Donnem, 2015, Stromal CD8+ T-cell density—a promising supplement to TNM staging in non-small cell lung cancer, Clin Cancer Res, 21, 2635, 10.1158/1078-0432.CCR-14-1905 Dacic, 2010, Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas, Mod Pathol, 23, 159, 10.1038/modpathol.2009.154 Gettinger, 2015, Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer, J Clin Oncol, 33, 2004, 10.1200/JCO.2014.58.3708 Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Govindan, 2012, Genomic landscape of non-small cell lung cancer in smokers and never-smokers, Cell, 150, 1121, 10.1016/j.cell.2012.08.024 Sholl, 2016, Programmed death ligand-1 immunohistochemistry- a new challenge for pathologists: a perspective from members of the Pulmonary Pathology Society, Arch Pathol Lab Med, 140, 341, 10.5858/arpa.2015-0506-SA Ilie, 2016, Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Ann Oncol, 27, 147, 10.1093/annonc/mdv489 McLaughlin, 2016, Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer, JAMA Oncol, 2, 46, 10.1001/jamaoncol.2015.3638 Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer (NSCLC): a retrospective analysis, Clin Cancer Res, 10.1158/1078-0432.CCR-15-3101